attributable, at least in part, to increased 3β-hydroxysteroid-∆24 reductase (DHCR24 or seladin-1) expression. 8 DHCR24 catalyzes the final step in cholesterol biosynthesis: the conversion of desmosterol to cholesterol. 9 It also has antioxidant 10 and antiapoptotic 11 properties and is potentially antiatherosclerotic. 8 We have shown that (A-I)rHDL inhibit TNF-α-induced inflammation in HCAECs by increasing DHCR24 gene expression and inhibiting nuclear factor (NF)-κB activation in an scavenger receptor class B type 1 (SR-B1)-dependent manner. 5 This inhibition was independent of changes in cellular cholesterol levels, cholesterol synthesis, and cholesterol efflux. 5 Heme oxygenases (HO) catalyze the oxidative cleavage of heme into equimolar amounts of CO, iron, and biliverdin, which is converted to bilirubin (BR) by biliverdin reductase. 12 Humans express 2 HO isoforms: an inducible isoform, HO-1 13 that protects against inflammation and oxidation, 12 and a constitutively expressed isoform, HO-2. 14 Mounting evidence suggests that pharmacological upregulation of HO-1 protects against atherosclerosis. For example, adenoviral-mediated expression of the HO-1 gene markedly reduces atherosclerosis and inhibits neointima formation in mice. 15, 16 HO-1 induction also protects against cardiac ischemia/reperfusion injury and pulmonary hypertension in animal models of cardiac transplant arteriosclerosis. 17 Inhibition of HO-1, in contrast, exacerbates atherosclerosis, 18, 19 and HO-1-deficient mice develop chronic inflammation. 20 There is evidence to suggest that HDL induce HO-1. For example, daily intraperitoneal injections of the apoA-I mimetic peptides D-4F and L-4F increase aortic HO-1 expression and activity in diabetic rats and obese mice. 21, 22 Upregulation of HO-1 by daily D-4F administration also reduces the intimal lesions that are associated with chronic rejection after mouse heart transplantation. 23 Furthermore, we have reported that HO-1 gene expression is increased significantly in HCAECs after incubation with (A-I)rHDL. 5 The present study determines whether the ability of lipidfree apoA-I and (A-I)rHDL to increase DHCR24 expression and reduce vascular inflammation can be explained in terms of the induction of HO-1.
Methods

Animal Studies
Chow-fed, normocholesterolemic NZW rabbits received a single intravenous infusion of lipid-free apoA-I (8 mg/kg) 24 hours before inserting a nonocclusive periarterial carotid collar (n=6/group). The animals were euthanized 24 hours after collar insertion. Endothelial expression of VCAM-1, ICAM-1, DHCR24, and neutrophil infiltration into the collared and noncollared carotid arteries was assessed immunohistochemically. DHCR24 and HO-1 mRNA and protein levels were quantified by real-time polymerase chain reaction and Western blotting, respectively. Microsomal HO activity was determined by high-performance liquid chromatography.
Vascular HO-1 and DHCR24 were knocked down by loading HO-1 and DHCR24 small interfering RNA (siRNA) into the space between the collar and carotid artery at the time of collar implantation. HO activity was inhibited systemically with daily intraperitoneal injections of tin-protoporphyrin-IX (SnPP). See Online Data Supplement for details.
Cell Culture
HCAECs were preincubated in the absence or presence of (A-I)rHDL, and then incubated with or without TNF-α tin-protoporphyrin IX (SnPP), a pharmacological inhibitor of HO activity, as described in the Online Data Supplement. In some experiments, the HCAECs were transfected with ATP binding cassette transporter A1 (ABCA1), ATP binding cassette transporter G1 (ABCG1), SR-B1, PDZ-domain-containing protein 1 (PDZK1; an adaptor molecule of SR-B1), DHCR24, HO-1, or scrambled siRNA before incubation with (A-I)rHDL, and, in some cases, stimulation with TNF-α. VCAM-1, ICAM-1, DHCR24, and HO-1 mRNA levels were quantified by real-time polymerase chain reaction. DHCR24 and HO-1 protein levels in cell lysates were determined by Western blotting.
In other experiments, HCAECs were incubated with specific extracellular signal-regulated kinase, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase, and phosphatidylinositol 3-kinase/Akt (PI3K/Akt) inhibitors before incubation with (A-I)rHDL and quantification of DHCR24 and HO-1 mRNA levels.
Statistics
Data are expressed as mean±SEM. One-way ANOVA and the Newman-Keuls post hoc test were used to evaluate differences between groups. All statistical analyses were carried out using GraphPad Prism software Version 4.03 (GraphPad Software, Inc, San Diego, CA). A P<0.05 was considered significant.
Results
Lipid-Free ApoA-I Inhibits Acute Vascular Inflammation and Increases DHCR24 and HO-1 Expression in NZW Rabbit Carotid Arteries
As reported previously, 6,7 placement of nonocclusive silastic collars around the carotid arteries of saline-infused NZW rabbits increased endothelial expression of VCAM-1 and ICAM-1 (Figures 1A and 1B ; P<0.05 for both). Carotid collar implantation also mediated neutrophil recruitment into the intima/media (CD18+ cells; P<0.05; Figure 1C ) but had no effect on endothelial DHCR24 protein expression ( Figure 1D ) or mRNA levels ( Figure 1E ). HO-1 mRNA levels ( Figure 1F ) and HO activity (assessed as BR production; Figure 1G ) were, in contrast, increased in the collared arteries (P<0.05 for both compared with noncollared arteries from saline-infused animals). A single lipid-free apoA-I infusion reduced the collarmediated increase in VCAM-1 ( Figure 1A ) and ICAM-1 ( Figure 1B ) expression and intima/media neutrophil infiltration ( Figure 1C ; P<0.05 compared with collared arteries from saline-infused animals). Infusion of lipid-free apoA-I also increased DHCR24 protein expression ( Figure 1D ) and mRNA levels ( Figure 1E ) in the collared arteries. HO-1 mRNA levels ( Figure 1F ) and HO activity ( Figure 1G ) were also increased in the collared arteries from the animals infused with apoA-I (P<0.05 compared with collared arteries from saline-infused animals).
Inhibition of Acute Vascular Inflammation in NZW Rabbits by Lipid-Free ApoA-I Depends on Increased DHCR24 and HO-1 Expression
To determine whether apoA-I inhibits vascular inflammation by increasing DHCR24 and HO-1 expression, an additional study was carried out in which DHCR24 and HO-1 were knocked down by loading DHCR24 siRNA and HO-1 siRNA into the space between the collar and the carotid artery. Scrambled siRNA was used as a control.
The saline-infused, control animals had low basal DHCR24 ( Figure 2A ) and HO-1 ( Figure 2B ) mRNA levels, which were minimally affected by placing DHCR24 siRNA between the collar and the carotid artery. The DHCR24 siRNA also had little effect on intima/media neutrophil infiltration into the collared arteries ( Figure 2C) .
A single infusion of lipid-free apoA-I increased DHCR24 (Figure 2A and 2E, open bars) and HO-1 ( Figure 2B and 2D, open bars) mRNA levels and inhibited infiltration of neutrophils into the intima/media ( Figure 2C and 2F, open bars) when scrambled siRNA was placed between the collar and the carotid artery.
Placement of DHCR24 siRNA between the collar and the carotid artery of the apoA-I-infused animals reduced DHCR24 (Figure 2A , closed bars) and HO-1 ( Figure 2B , closed bars) mRNA levels and also reduced the ability of apoA-I to inhibit infiltration of neutrophils ( Figure 2C , closed bars) into the intima/media (P<0.05 for all compared with saline-infused animals). Placement of HO-1 siRNA into the space between the collar and the carotid artery of the saline-infused animals had little effect on the low basal HO-1 ( Figure 2D ) and DHCR24 ( Figure 2E ) mRNA levels or on collar-induced intima/media neutrophil infiltration ( Figure 2F ). When HO-1 siRNA was placed inside the collars of the lipid-free apoA-I-infused animals, HO-1 mRNA levels ( Figure 2D , closed bars) were reduced, as was the inhibition of intima/media neutrophil infiltration ( Figure 2F , closed bars; P<0.05 for both compared with saline-infused animals). The apoA-I-mediated increase in DHCR24 mRNA levels was, in contrast, unaffected when HO-1 siRNA was placed between the collar and the carotid artery ( Figure 2D , closed bar).
The effects of inhibiting HO activity systemically with SnPP were also investigated. Daily intraperitoneal injections of SnPP into collared, saline-infused animals did not alter HO-1 ( Figure 2G ) or DHCR24 mRNA levels ( Figure 2H ) or intima/media neutrophil infiltration ( Figure 2I ), nor did it prevent apoA-I from increasing HO-1 ( Figure 2G ) and DHCR24 ( Figure 2H ) mRNA levels. However, lipid-free apoA-I was no longer able to inhibit neutrophil infiltration into collared carotid arteries of the SnPP-treated animals ( Figure 2I ; P<0.05).
(A-I)rHDL Increase DHCR24 and HO-1 mRNA and Protein Levels in HCAECs
The ability of apoA-I to increase DHCR24 expression and induce HO-1 was further investigated in HCAECs. Because lipid-free apoA-I is rapidly incorporated into the plasma HDL fraction when administered intravenously to rabbits, 8 these studies were carried out with discoidal (A-I)rHDL.
Incubation of nonactivated HCAECs with (A-I)rHDL increased DHCR24 ( Figure 3A ) and HO-1 ( Figure 3B ), but not HO-2 ( Figure 3F ) protein levels in a concentration-dependent manner relative to cells incubated in the absence of (A-I)rHDL. DHCR24 ( Figure 3C ) and HO-1 ( Figure 3D ) mRNA levels, as well as HO activity ( Figure 3E ), also increased under these conditions (P<0.05 for all).
Incubation with (A-I)rHDL had no effect on oxidized glutathione (GSSG) levels in nonactivated HCAECs (Online Figure I ). This indicates that the (A-I)rHDL-mediated increase in DHCR24 and HO-1 protein and mRNA levels and HO-1 activity is independent of intracellular oxidative stress.
DHCR24 and HO-1 mRNA levels also increased when human coronary artery smooth muscle cells were incubated with (A-I)rHDL (Online Figure II) . In the case of DHCR24, the increase in mRNA levels was similar for HCAECs and human coronary artery smooth muscle cells, whereas incubation with (A-I)rHDL increased HO-1 mRNA levels to a greater extent in HCAECs than in human coronary artery smooth muscle cells. This result indicates that DHCR24 and HO-1 were most likely knocked down in both cell types in the in vivo study in Figure 2 .
(A-I)rHDL Inhibit Cytokine-Induced Inflammation in HCAECs by Increasing DHCR24 and HO-1 Expression
To determine whether (A-I)rHDL inhibit inflammation in endothelial cells in a DHCR24-and HO-1-dependent manner, HCAECs were transfected with DHCR24 siRNA, HO-1 siRNA, or scrambled siRNA (siControl). The cells were then incubated in the absence or presence of (A-I)rHDL before activation with TNF-α and quantification of VCΑΜ-1 and ΙCΑΜ-1 mRNA levels. VCAM-1 ( Figure 4A and 4C, open bars) and ICAM-1 mRNA levels ( Figure 4B and 4D, open bars) were both increased in the TNF-α-activated HCAECs that were transfected with scrambled siRNA (P<0.05 for both). Preincubation of the scrambled siRNA-transfected cells with (A-I)rHDL inhibited the TNF-α-mediated increase in VCAM-1 ( Figure 4A and 4C, open bars) and ICAM-1 mRNA levels ( Figure 4B and 4D, open bars; P<0.05 for both). Transfection of nonactivated HCAECs with DHCR24 si-RNA and HO-1 siRNA did not increase VCAM-1 ( Figure 4A and 4C, closed bars) or ICAM-1 ( Figure 4B and 4D, closed bars) mRNA levels. When the transfected cells were incubated with TNF-α, both VCAM-1 ( Figure 4A and 4C, closed bars) and ICAM-1 ( Figure 4B and 4D, closed bars) mRNA levels increased (P<0.05). In contrast to what was observed for HCAECs transfected with scrambled siRNA, preincubation of the DHCR24 siRNA-and HO-1 siRNA-transfected HCAECs with (A-I)rHDL did not attenuate the TNF-α-mediated increase in either VCΑΜ-1 ( Figure 4A and 4C, closed bars) or ΙCΑΜ-1 ( Figure 4B and 4D, closed bars) mRNA levels.
Nontransfected HCAECs were also preincubated in the presence and absence of (A-I)rHDL with and without SnPP before activation with TNF-α. Incubation of the HCAECs with either TNF-α alone, or with ΤΝF-α plus SnPP increased VCAM-1 ( Figure 4E ) and ICAM-1 mRNA levels ( Figure 4F ; P<0.05 for both). Preincubation of the HCAECs with (A-I)rHDL, before activation with TNF-α in the absence of SnPP, attenuated the increase in VCAM-1 ( Figure 4E , open bars) and ICAM-1 mRNA levels ( Figure 4F , open bars; P<0.05 for both). When, in contrast, SnPP was included in the incubations, the (A-I)rHDL were no longer able to inhibit the TNF-α-mediated increase in VCAM-1 and ICAM-1 mRNA levels ( Figure 4E and 4F, closed bars). Taken together, these results indicate that (A-I)rHDL inhibit cytokine-induced inflammation in HCAECs by increasing DHCR24 expression and inducing HO-1.
The HO-1 Metabolic Product, BR, Mimics the Anti-inflammatory Effects of (A-I)rHDL
We also asked whether the anti-inflammatory effects of (A-I)rHDL could be attributed to formation of the HO-1 metabolic products, BR, CO, and iron. Incubation of TNF-α-activated HCAECs with BR inhibited the TNF-α-mediated increase in VCAM-1 and ICAM-1 mRNA levels (P<0.05; Online Figure IIIA ). CO and iron were, in contrast, unable to reduce VCAM-1 and ICAM-1 mRNA levels in TNF-α-activated HCAECs (Online Figure IIIA) . BR also inhibited the TNF-α-mediated nuclear translocation of the NF-κB p65 subunit (Online Figure IIIB) and reduced the TNF-α-mediated increase in intracellular GSSG levels (Online Figure IIIC; P<0.05 for all). These effects of BR are consistent with what we have reported previously for the inhibition of TNF-α-induced activation of NF-κB 5 and oxidative stress 24 by (A-I)rHDL.
Induction of HO-1 by (A-I)rHDL Is Dependent on Increased DHCR24 Expression
The result showing that induction of HO-1 by apoA-I is inhibited in collared NZW rabbit carotid arteries when DHCR24 is knocked down (Figure 2B ), but that knockdown of HO-1 does not prevent apoA-I from increasing DHCR24 mRNA levels ( Figure 2E ), suggests that upregulation of DHCR24 expression is required for the induction of HO-1. This possibility was investigated by quantifying DHCR24 and HO-1 mRNA and protein levels in HCAECs transfected with DHCR24 siRNA, HO-1 siRNA, or scrambled siRNA (siControl) before incubation in the absence or presence of (A-I)rHDL. Transfection of HCAECs with DHCR24 siRNA and HO-1 siRNA did not affect basal DHCR24 and HO-1 mRNA and protein levels (Figure 5A-5D ; Online Figure IVA and IVB), nor was there any effect on HO activity (Online Figure IVC) . As HO-1 mRNA and protein levels in these cells were very low, it follows that the HO activity shown in Online Figure  IVC reflects constitutive HO-2 expression, which is not altered by incubation with (A-I)rHDL ( Figure 3F ).
Both DHCR24 ( Figure 5A and 5D, open bars) and HO-1 ( Figure 5B and 5C, open bars) mRNA and protein (Online Figure IVA and IVB, open bars) levels increased when HCAECs were transfected with scrambled siRNA and incubated with (A-I)rHDL (P<0.05 for all). HO activity also increased under these conditions (Online Figure IVC, open bars) .
The (A-I)rHDL-mediated increases in HO-1 mRNA ( Figure 5C ) and protein (Online Figure IVB) levels and activity of HO (Online Figure IVC) were attenuated in HCAECs transfected with HO-1 siRNA. The capacity of (A-I)rHDL to increase HO-1 mRNA levels was also impaired in the cells Figure 5B ). The ability of (A-I)rHDL to increase DHCR24 mRNA levels, in contrast, was unaffected in HCAECs that were transfected with HO-1 siRNA ( Figure 5D ).
These results were further confirmed in nontransfected HCAECs preincubated in the presence and absence of (A-I) rHDL, with and without SnPP. Incubation with SnPP in the absence of (A-I)rHDL did not affect HO-1 or DHCR24 mRNA levels ( Figure 5E and 5F ). When the cells were incubated with (A-I)rHDL in the absence of SnPP, both HO-1 and DHCR24 mRNA levels increased ( Figure 5E and 5F, open bars; P<0.05 for both). Inclusion of SnPP in the incubations had no effect on the ability of (A-I)rHDL to increase HO-1 or DHCR24 mRNA levels ( Figure 5E and 5F, closed bars).
When taken together, these results confirm that the (A-I) rHDL-mediated induction of HO-1 is dependent on increased expression of DHCR24.
(A-I)rHDL Increase DHCR24 Expression and Induce HO-1 in an SR-B1-and PDZK1-Dependent Manner
To investigate the mechanism by which (A-I)rHDL increase DHCR24 expression and induce HO-1, HCAECs were transfected with ABCA1 siRNA, ABCG1 siRNA, SR-B1 siRNA, PDZK1 siRNA, and scrambled siRNA (siControl), and then incubated in the absence or presence of (A-I)rHDL. Transfection with scrambled siRNA did not affect ABCA1, ABCG1, SR-B1, PDZK1, DHCR24, or HO-1 mRNA levels (not shown). Transfection with the respective siRNAs decreased ABCA1, ABCG1, and SR-B1 mRNA levels by 62±5.4%, 71±4.1%, and 56±3.4%, whereas PDZK1 protein levels were reduced by 53±4.1%.
Transfection of HCAECs with scrambled siRNA, ABCA1 siRNA, ABCG1 siRNA, SR-B1 siRNA, and PDZK1 siRNA followed by incubation in the absence of (A-I)rHDL had no effect on DHCR24 and HO-1 mRNA levels ( Figure 6A and 6B).
When incubated in the presence of (A-I)rHDL, HO-1 and DHCR24 mRNA levels increased to a comparable extent in HCAECs transfected with scrambled siRNA ( Figure 6A and 6B, open bars), ABCA1 siRNA, or ABCG1 siRNA ( Figure  6A and 6B, closed bars; P<0.05 for all). However, when the HCAECs were transfected with SR-B1 siRNA or PDZK1 siRNA, and then incubated with (A-I)rHDL, neither DHCR24 ( Figure 6A , closed bars) nor HO-1 mRNA levels ( Figure 6B , closed bars) increased. This is consistent with (A-I)rHDL increasing DHCR24 and HO-1 mRNA levels in an SR-B1-and PDZK1-dependent manner.
(A-I)rHDL Increase DHCR24 Expression and Induce HO-1 by Activating the PI3K/Akt Signaling Pathway
The signaling pathway responsible for increasing DHCR24 expression and inducing HO-1 in HCAECs was also identified. HCAECs were preincubated with specific inhibitors of extracellular signal-regulated kinase (PD98059), c-Jun N-terminal kinase (SP600125), p38 mitogen-activated protein kinase (SB203580), and PI3K/Akt (LY294002), before incubation with (A-I)rHDL. When the HCAECs were incubated in the presence of (A-I)rHDL only, HO-1 ( Figure 7A, open bars) and DHCR24 ( Figure 7B , open bars) mRNA levels increased (P<0.05). The ability of (A-I)rHDL to increase DHCR24 and HO-1 mRNA levels was not affected when the cells were preincubated with the extracellular signal-regulated kinase, c-Jun N-terminal kinase, or p38 mitogen-activated protein kinase inhibitors ( Figure 7A and 7B, closed bars) . However, when the cells were preincubated with the PI3K/Akt inhibitor, LY294002, the induction of HO-1 decreased significantly ( Figure 7A ; P<0.05), whereas the DHCR24 mRNA levels remained unchanged ( Figure 7B ).
To ascertain whether activation of PI3K/Akt was dependent on increased DHCR24 expression, HCAECs were transfected with DHCR24 siRNA or scrambled siRNA (siControl) before incubation in the absence or presence of (A-I)rHDL. Transfection with scrambled siRNA had no effect on phosphorylated-Akt protein levels (not shown). Incubation with (A-I)rHDL increased phosphorylated-Akt protein levels (P<0.05) in the scrambled siRNA-transfected cells ( Figure  7C , open bars), but not in the DHCR24 siRNA-transfected HCAECs (P<0.05; Figure 7C , closed bars). This indicates that the (A-I)rHDL-mediated increase in DHCR24 expression activates the PI3K/Akt signal transduction pathway, which subsequently induces HO-1.
Discussion
We have previously reported that intravenous infusions of discoidal (A-I)rHDL and lipid-free apoA-I are equally effective in inhibiting acute vascular inflammation in NZW rabbit carotid arteries. 6, 7 We have also established that discoidal (A-I)rHDL inhibit TNF-α-induced inflammation in cultured human endothelial cells 3, 4 in an SR-B1-dependent manner by a process involving increased expression of DHCR24 and inhibition of NF-κB activation. 5 We now identify for the first time an additional, novel mechanism of action for the antiinflammatory effects of (A-I)rHDL, whereby the interaction of (A-I)rHDL with SR-B1 and its adaptor protein PDZK1 increases DHCR24 expression, which activates the PI3K/Akt signal transduction pathway and induces HO-1 (Figure 8 ).
Coordinated regulation of DHCR24 and HO-1 expression by factors other than lipid-free apoA-I and (A-I)rHDL has been reported previously. For example, hydrogen peroxide increases DHCR24 expression in human-derived neuroblastoma cells 25 and induces HO-1 expression in human dental pulp cells. 26 Thyroid hormones 27 and estrogen 28 increase DHCR24 expression in human fetal neuroepithelial cells and also enhance HO-1 expression in the rat kidney 29 and intestine. 30 However, high dietary intake of the trace metal selenium reduces DHCR24 expression in the rat prostate, 31 whereas bovine aortic endothelial cells cultured in selenium-deficient medium have increased expression of HO-1. elements in the gene promoter region that can be stimulated by a range of transcription factors. 12 Several signaling pathways, including mitogen-activated protein kinase, protein kinase C, and PI3K/Akt, are known to induce HO-1 in a wide range of cell types. 12, 33 It is noteworthy that many of these signaling pathways are activated by HDL via SR-B1-dependent mechanisms. 34, 35 The PI3K/Akt signaling pathway has also been implicated in the cardioprotective properties of HDL. For example, activation of endothelial NO synthase by HDL involves PI3K/ Akt and mitogen-activated protein kinase signaling pathways and is SR-B1-dependent. 36 Activation of PI3K/Akt by HDL suppresses endothelial cell apoptosis, 37 and HDL also induce PI3K/Akt-dependent transforming growth factor-β2 expression in endothelial cells. 38 This is relevant to the current study because the transforming growth factor-β family modulates vascular inflammatory responses. 39 Discoidal (A-I)rHDL also stimulate endothelial progenitor cell differentiation via the PI3K/Akt pathway. 40 The current results extend these observations by showing for the first time that activation of PI3K/Akt by (A-I)rHDL induces HO-1. Because 1-palmitoyl-2-linoleoyl phosphatidylcholine was the only phospholipid in the rHDL preparations, the induction of HO-1 could not be attributed to biologically active lipids that are transported by HDL, such as lysophosphatidylcholine 41 or sphingosine-1-phosphate. 42 Other investigators have shown that Akt phosphorylation in DHCR24-deficient mouse embryonic fibroblasts is significantly reduced relative to wild-type mouse embryonic fibroblasts. 43 This suggests that activation of Akt signaling is, at least in part, dependent on DHCR24. When this observation is combined with the present results showing that Akt phosphorylation by (A-I)rHDL is DHCR24-dependent ( Figure  7C ) and that PI3K/Akt activation is required for HO-1 induction ( Figure 7A ), it follows that the activation of PI3K/Akt by (A-I)rHDL is, at least in part, a result of upregulation of DHCR24 expression, which increases HO-1 activity and inhibits the inflammatory response (Figure 8 ).
SR-B1 is a cell surface receptor that selectively depletes HDL of cholesteryl esters 44 and exports cholesterol from cell membranes to HDL. 45 Some of the cardioprotective effects of HDL are mediated by binding to SR-B1. For example, HDLinduced endothelial NO synthase activation, 36 promotion of endothelial cell migration and reendothelialization, 46 as well as increased glucose uptake by adipocytes and glycogen synthesis in muscle cells 47 all involve HDL-SR-B1 interactions and the PI3K/Akt signaling pathway. We have also reported that (A-I)rHDL increase DHCR24 expression in HCAECs in an SR-B1-dependent manner. 5 The present results confirm and extend the latter observation by establishing that these events are dependent on the SR-B1 adaptor protein, PDZK1.
We have also reported that upregulation of DHCR24 gene expression by (A-I)rHDL is independent of cholesterol biosynthesis and the efflux of cholesterol from endothelial cells. 5 In that study, we showed that incubation with cyclodextrin, which depletes HCAECs of cholesterol and increases cholesterol biosynthesis, did not prevent (A-I)rHDL from increasing DHCR24 mRNA levels or reducing VCAM-1 expression in TNF-α-activated cells. Furthermore, inhibition of HCAEC cholesterol biosynthesis with simvastatin reduced DHCR24 expression but did not increase VCAM-1 expression. 5 This is consistent with the elevated VCAM-1 expression in HCAECs in which DHCR24 was knocked down being independent of cholesterol synthesis.
An insight into the temporal relationship between the ability of (A-I)rHDL to increase DHCR24 and HO-1 mRNA and protein levels and reduce the expression of VCAM-1 and ICAM-1 in endothelial cells can also be obtained by considering the current results in light of an earlier study from this laboratory. The previous study established that VCAM-1 and ICAM-1 expression is very low in nonactivated endothelial cells and not increased by incubation with HDL. 3 As the present results also establish that VCAM-1 and ICAM-1 protein and mRNA levels do not increase when DHCR24 and HO-1 are knocked down ( Figure 4A-4D) , it follows that the (A-I)rHDL-mediated increase in DHCR24 and HO-1 protein and mRNA levels and HO activity not only precedes, but is also independent from, the TNF-α-induced increase in endothelial VCAM-1 and ICAM-1 expression.
We have shown previously that (A-I)rHDL reduce inflammation in cytokine-activated HCAECs by inhibiting the canonical NF-κB pathway and attenuating VCAM-1 and ICAM-1 expression. 5 The present study identifies another anti-inflammatory mechanism, in which the (A-I)rHDL-mediated increase in DHCR24 expression activates PI3K/Akt signal transduction and increases HO-1 activity. The relative contributions of each pathway to the anti-inflammatory properties of (A-I)rHDL remain to be clarified. Furthermore, we do not know whether other types of HDL, for example, those that contain apoA-II, apoE, or apoA-IV, also inhibit inflammation via the NF-κB pathway and the SR-B1-PDZK1-DHCR24-PI3K/Akt-HO-1 pathway, or whether inhibition of these pathways is differentially regulated under varying pathophysiological conditions. Evidence that additional pathways may also be involved in the induction of HO-1 comes from Figure  1D , 1F, and 1G, which shows that implantation of a carotid collar increases HO-1 mRNA levels and HO activity in the absence of increased DHCR24 expression in saline-infused NZW rabbits.
In conclusion, this study identifies a novel mechanism of the anti-inflammatory properties of HDL that can potentially be exploited to inhibit inflammation and treat cardiovascular disease.
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